Impact of metformin on disease control and survival in patients with head and neck cancer: a retrospective cohort study
Abstract Objective A number of in vitro and clinical studies have suggested potential antineoplastic effects of metformin. The impact of this medication on outcomes in head and neck cancer is less clear. Our aim was to determine the effect of metformin on outcomes within our large cohort of head and...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-07-01
|
| Series: | Journal of Otolaryngology - Head and Neck Surgery |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40463-019-0348-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568852755513344 |
|---|---|
| author | Daniel J. Lee Caitlin P. McMullen Andrew Foreman Shao Hui Huang Lin Lu Wei Xu John R. de Almeida Geoffrey Liu Scott V. Bratman David P. Goldstein |
| author_facet | Daniel J. Lee Caitlin P. McMullen Andrew Foreman Shao Hui Huang Lin Lu Wei Xu John R. de Almeida Geoffrey Liu Scott V. Bratman David P. Goldstein |
| author_sort | Daniel J. Lee |
| collection | DOAJ |
| description | Abstract Objective A number of in vitro and clinical studies have suggested potential antineoplastic effects of metformin. The impact of this medication on outcomes in head and neck cancer is less clear. Our aim was to determine the effect of metformin on outcomes within our large cohort of head and neck cancer patients with Type II Diabetes (T2DM). Study design Retrospective cohort study. Setting Tertiary Cancer Centre. Subjects and methods A retrospective review of individuals with head and neck squamous carcinoma (HNSCC) and T2DM between January 2005 and December 2011 at Princess Margaret Cancer Centre was conducted. Medication history was obtained from surveys at initial presentation and electronic medical record review. Using Cox regression analyses, the association between metformin use and local, regional and distant failures was explored. Subgroup analyses were conducted for oral cavity, oropharynx and larynx. Results A total of 329 HNSCC patients with T2DM were identified, including 195 metformin users and 134 non-metformin users. Patients were well-matched in terms of clinical, pathologic, and treatment factors. No difference in local, regional, or distant failure was observed between diabetic metformin users and diabetic non-metformin users for the entire cohort or within subgroup analysis for subsite. No difference between the two groups was observed for overall survival, recurrence-free survival, and disease-specific survival at 5 years. Conclusion No association between metformin use and oncologic outcomes were observed in this large cohort of HNSCC patients. Multicenter, prospective studies may be needed to verify previous studies identifying a potential anti-neoplastic effect of this medication. |
| format | Article |
| id | doaj-art-8515aa6c4632422785c309f2fad171e2 |
| institution | Kabale University |
| issn | 1916-0216 |
| language | English |
| publishDate | 2019-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Otolaryngology - Head and Neck Surgery |
| spelling | doaj-art-8515aa6c4632422785c309f2fad171e22025-02-03T00:22:58ZengSAGE PublishingJournal of Otolaryngology - Head and Neck Surgery1916-02162019-07-0148111310.1186/s40463-019-0348-5Impact of metformin on disease control and survival in patients with head and neck cancer: a retrospective cohort studyDaniel J. Lee0Caitlin P. McMullen1Andrew Foreman2Shao Hui Huang3Lin Lu4Wei Xu5John R. de Almeida6Geoffrey Liu7Scott V. Bratman8David P. Goldstein9Department of Otolaryngology Head and Neck Surgery/Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of TorontoDepartment of Otolaryngology Head and Neck Surgery/Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of TorontoDepartment of Otolaryngology Head and Neck Surgery/Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of TorontoDepartment of Radiation Oncology, University Health Network, Princess Margaret Cancer Centre, University of TorontoBiostatistics Department, Princess Margaret Cancer Centre and Dalla Lana School of Public Health, University of TorontoBiostatistics Department, Princess Margaret Cancer Centre and Dalla Lana School of Public Health, University of TorontoDepartment of Otolaryngology Head and Neck Surgery/Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of TorontoBiostatistics Department, Princess Margaret Cancer Centre and Dalla Lana School of Public Health, University of TorontoDepartment of Radiation Oncology, University Health Network, Princess Margaret Cancer Centre, University of TorontoDepartment of Otolaryngology Head and Neck Surgery/Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of TorontoAbstract Objective A number of in vitro and clinical studies have suggested potential antineoplastic effects of metformin. The impact of this medication on outcomes in head and neck cancer is less clear. Our aim was to determine the effect of metformin on outcomes within our large cohort of head and neck cancer patients with Type II Diabetes (T2DM). Study design Retrospective cohort study. Setting Tertiary Cancer Centre. Subjects and methods A retrospective review of individuals with head and neck squamous carcinoma (HNSCC) and T2DM between January 2005 and December 2011 at Princess Margaret Cancer Centre was conducted. Medication history was obtained from surveys at initial presentation and electronic medical record review. Using Cox regression analyses, the association between metformin use and local, regional and distant failures was explored. Subgroup analyses were conducted for oral cavity, oropharynx and larynx. Results A total of 329 HNSCC patients with T2DM were identified, including 195 metformin users and 134 non-metformin users. Patients were well-matched in terms of clinical, pathologic, and treatment factors. No difference in local, regional, or distant failure was observed between diabetic metformin users and diabetic non-metformin users for the entire cohort or within subgroup analysis for subsite. No difference between the two groups was observed for overall survival, recurrence-free survival, and disease-specific survival at 5 years. Conclusion No association between metformin use and oncologic outcomes were observed in this large cohort of HNSCC patients. Multicenter, prospective studies may be needed to verify previous studies identifying a potential anti-neoplastic effect of this medication.http://link.springer.com/article/10.1186/s40463-019-0348-5Head and neck cancerDiabetesMetformin |
| spellingShingle | Daniel J. Lee Caitlin P. McMullen Andrew Foreman Shao Hui Huang Lin Lu Wei Xu John R. de Almeida Geoffrey Liu Scott V. Bratman David P. Goldstein Impact of metformin on disease control and survival in patients with head and neck cancer: a retrospective cohort study Journal of Otolaryngology - Head and Neck Surgery Head and neck cancer Diabetes Metformin |
| title | Impact of metformin on disease control and survival in patients with head and neck cancer: a retrospective cohort study |
| title_full | Impact of metformin on disease control and survival in patients with head and neck cancer: a retrospective cohort study |
| title_fullStr | Impact of metformin on disease control and survival in patients with head and neck cancer: a retrospective cohort study |
| title_full_unstemmed | Impact of metformin on disease control and survival in patients with head and neck cancer: a retrospective cohort study |
| title_short | Impact of metformin on disease control and survival in patients with head and neck cancer: a retrospective cohort study |
| title_sort | impact of metformin on disease control and survival in patients with head and neck cancer a retrospective cohort study |
| topic | Head and neck cancer Diabetes Metformin |
| url | http://link.springer.com/article/10.1186/s40463-019-0348-5 |
| work_keys_str_mv | AT danieljlee impactofmetforminondiseasecontrolandsurvivalinpatientswithheadandneckcanceraretrospectivecohortstudy AT caitlinpmcmullen impactofmetforminondiseasecontrolandsurvivalinpatientswithheadandneckcanceraretrospectivecohortstudy AT andrewforeman impactofmetforminondiseasecontrolandsurvivalinpatientswithheadandneckcanceraretrospectivecohortstudy AT shaohuihuang impactofmetforminondiseasecontrolandsurvivalinpatientswithheadandneckcanceraretrospectivecohortstudy AT linlu impactofmetforminondiseasecontrolandsurvivalinpatientswithheadandneckcanceraretrospectivecohortstudy AT weixu impactofmetforminondiseasecontrolandsurvivalinpatientswithheadandneckcanceraretrospectivecohortstudy AT johnrdealmeida impactofmetforminondiseasecontrolandsurvivalinpatientswithheadandneckcanceraretrospectivecohortstudy AT geoffreyliu impactofmetforminondiseasecontrolandsurvivalinpatientswithheadandneckcanceraretrospectivecohortstudy AT scottvbratman impactofmetforminondiseasecontrolandsurvivalinpatientswithheadandneckcanceraretrospectivecohortstudy AT davidpgoldstein impactofmetforminondiseasecontrolandsurvivalinpatientswithheadandneckcanceraretrospectivecohortstudy |